News | June 14, 2021
Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Emtricitabine and Tenofovir Disoproxil Fumarate tablets had estimated annual sales of US $2.1 billion in the U.S. according to IQVIA MAT March 2021
Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets
The company is doubling its chemistry research capacity that should commission by Q2'FY22
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
Aurobindo has one of the most enduring generics ecosystems among peers
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
Subscribe To Our Newsletter & Stay Updated
